No. pts. | Median (range) | |||
Before prostatectomy | PSA (ng/ml) | 16 | 8.4 (4.2 - 18) | |
3 + 3 | 4 | |||
3 + 4 | 6 | |||
Gleason score | 4 + 3 | 2 | ||
4 + 4 | 2 | |||
4 + 5 | 2 | |||
T1c | 8 | |||
Clinical stage | T2a | 6 | ||
T2b | 2 | |||
Low | 2 | |||
Risk group (D’Amico) | Intermediate | 10 | ||
High | 4 | |||
Before HIFU | PSA (ng/ml) | 16 | 0.98 (0.318 - 3.2) | |
3 + 3 | 2 | |||
3 + 4 | 8 | |||
Gleason score | 4 + 3 | 3 | ||
4 + 4 | 1 | |||
5 + 4 | 2 | |||
pT2a | 3 | |||
Pathological stage | pT2b | 9 | ||
pT3a | 3 | |||
pT3b | 1 | |||
Risk group (after prostatectomy) | Intermediate | 10 | ||
High | 6 |